Effect of noninvasive vagus nerve stimulation on acute migraine: An open-label pilot study

Goadsby, PJ; Grosberg, Brian M.; Mauskop, Alexander; Cady, Roger; Simmons, Kathy

doi:10.1177/0333102414524494

Cited by 179 publications

(163 citation statements)

References 47 publications

Supporting

Mentioning

151

Contrasting

Unclassified

Order By: Relevance

“…They are usually mild to moderate and seldom require that the device be explanted (47). Recently, 2 types of noninvasive transcutaneous VNS (t-VNS) devices, safe and tolerable alternative treatments, were developed, and they are in clinical trials for epilepsy, depression, and migraine (48)(49)(50)(51). These noninvasive devices might be effective in disorders classically treated with VNS and could potentially be applied to inflammation-related disorders.…”

Section: Feasibility Of Vns As a Means Of Reducing Renal Injurymentioning

confidence: 99%

Vagus nerve stimulation mediates protection from kidney ischemia-reperfusion injury through α7nAChR+ splenocytes

Inoue¹,

Abe²,

Sung³

et al. 2016

Journal of Clinical Investigation

242

296

View full text Add to dashboard Cite

) for measuring NE, the George F. O'Brien Center, University of Alabama (P30DK079337; principal investigator, Anupam Agarwal) for measuring plasma creatinine by LC-MS, the UVA Research Histology Core for their assistance in preparation of histology slides, and the UVA Flow Cytometry Facility for sample analysis using the Luminex 100 IS system and FACS sorting using BD Influx. We also thank Primetech Corp. (Tokyo, Japan) for supplying the iPRECIO microinfusion pump system.

show abstract

Section: Feasibility Of Vns As a Means Of Reducing Renal Injurymentioning

confidence: 99%

Vagus nerve stimulation mediates protection from kidney ischemia-reperfusion injury through α7nAChR+ splenocytes

Inoue¹,

Abe²,

Sung³

et al. 2016

Journal of Clinical Investigation

242

296

View full text Add to dashboard Cite

show abstract

“…In an open-label, single-arm, multipleattack pilot study, 27 patients with EM treated 80 migraine attacks acutely with 2, 90-s nVNS treatments [10]. In double-blind, sham-controlled pilot RCT using nVNS to prevent CM, 59 patients received 2, 90-s stimulations 3 times a day for 2 months, followed by a 6-month openlabel phase [11].…”

Section: Transcutaneous Vagal Nerve Stimulatormentioning

confidence: 99%

Emerging treatments for the primary headache disorders

2015

View full text Add to dashboard Cite

Migraine and cluster headache are common, episodic, often chronic and disabling disorders of the brain. Although there are many standard treatment techniques, none are ideal. This article reviews various novel pharmacologic and device-related treatments for migraine and cluster headache. Emphasis is given to recent advances in the development of monoclonal antibodies (mAbs) targeting calcitonin gene-related peptide (CGRP) and its receptor, including promising results from phase 2 trials studying the safety and efficacy of LY2951742, ALD403 and TEV-48125, three anti-CGRP mAbs. Other new pharmacologic treatments discussed include the 5-HT1F receptor agonist lasmiditan and glial cell modulator ibudilast. Also reviewed is neuromodulation for migraine and cluster headache, including promising recent results of randomized controlled trials studying sphenopalatine ganglion stimulation, trigeminal nerve stimulation, transcutaneous vagus nerve stimulation, and transcranial magnetic stimulation. Finally, we discuss patch, inhaled, and intranasal methods of triptan and dihydroergotamine delivery.

show abstract

“…Gammacore® is a portable non-invasive VNS (nVNS) that transmits a small electrical signal to the vagus nerve through the skin when held against the neck [40]. In an open-label pilot study including 27 patients using nVNS to treat acute migraine, 21% were pain-free at 2 hours while 42% reported an improvement [41]. Raneiro et al treated 15 patients (362 attacks) with CM and medication overuse headache (CM/MOH) using nVNS [40].…”

Section: Non-invasive Vagal Nerve Stimulationmentioning

confidence: 99%

New and Emerging Treatments for Migraine

Ahmed¹

2015

J Pain Relief

View full text Add to dashboard Cite

Migraine can be extremely disabling with a considerable impact on the life of an individual in their ability to work or perform activities of daily living. The arrival of 'triptans' in the early 1990s saw a major change in the way migraines were treated, and 'triptans' remain the gold standard in treating an acute attack. For a long time there was very little progress in identifying new targets for acute treatment and there was virtually nothing new in migraine prevention. However, in recent times, considerable research has been made in understanding the pathophysiology of migraine and the coming decade should see a drastic change in treating and preventing migraines with potential neuro-pharmacological agents and non-invasive neuro-stimulation. This article briefly discusses the pathophysiology of migraine and reviews new therapeutic options as well as some promising treatments undergoing clinical trials.

show abstract

Effect of noninvasive vagus nerve stimulation on acute migraine: An open-label pilot study

Abstract: nVNS may be an effective and well-tolerated acute treatment for migraine in certain patients.

Cited by 179 publications

References 47 publications

Vagus nerve stimulation mediates protection from kidney ischemia-reperfusion injury through α7nAChR+ splenocytes

Vagus nerve stimulation mediates protection from kidney ischemia-reperfusion injury through α7nAChR+ splenocytes

Emerging treatments for the primary headache disorders

New and Emerging Treatments for Migraine

Contact Info

Product

Resources

About